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Macrophage-specific Abca1 knock-out (Abca1M/M) mice
were generated to determine the role of macrophage ABCA1
expression in plasma lipoprotein concentrations and the innate
immune response ofmacrophages. Plasma lipid and lipoprotein
concentrations in chow-fed Abca1M/M and wild-type (WT)
mice were indistinguishable. ComparedwithWTmacrophages,
Abca1M/M macrophages had a >95% reduction in ABCA1
protein, failed to efflux lipid to apoA-I, and had a significant
increase in free cholesterol (FC) andmembrane lipid rafts with-
out induction of endoplasmic reticulum stress. Lipopolysaccha-
ride (LPS)-treated Abca1M/M macrophages exhibited
enhanced expression of pro-inflammatory cytokines and
increased activation of the NF-B and MAPK pathways, which
could be diminished by silencingMyD88 or by chemical inhibi-
tion of NF-B or MAPK. In vivo LPS injection also resulted in a
higher pro-inflammatory response in Abca1M/M mice com-
pared with WT mice. Furthermore, cholesterol depletion of
macrophages with methyl--cyclodextrin normalized FC con-
tent between the two genotypes and their response to LPS; cho-
lesterol repletion of macrophages resulted in increased cellular
FC accumulation and enhanced cellular response to LPS. Our
results suggest thatmacrophageABCA1expressionmayprotect
against atherosclerosis by facilitating the net removal of excess
lipid from macrophages and dampening pro-inflammatory
MyD88-dependent signaling pathways by reduction of cell
membrane FC and lipid raft content.
ABCA1 (ATP-binding cassette transporter A1) is a plasma
membrane protein that is widely expressed throughout the
body (1, 2) and functions as a primary gatekeeper for eliminat-
ing excess free cholesterol (FC)2 from tissues by effluxing cel-
lular FC and phospholipid (PL) to lipid-free apoA-I, resulting in
the formation of nascent high density lipoprotein (HDL) parti-
cles (3, 4). The nascent discoid-shaped HDL then undergoes a
maturation process that involves additional lipid acquisition
and conversion of FC to cholesteryl ester (CE) by lecithin:cho-
lesterol acyltransferase to become mature spherical plasma
HDL. Mutations that inactivate the human ABCA1 gene result
in Tangier disease, which is characterized by extremely low
HDL cholesterol concentrations, mildly elevated plasma tri-
gelyceride levels, and accumulation of cholesterol in macro-
phages (5–10). Targeted deletion of Abca1 in mice and a natu-
ral mutation of Abca1 in the Wisconsin hypoalpha mutant
chicken recapitulate the Tangier plasma lipid phenotype, sup-
porting the essential role of ABCA1 inHDL formation (11–15).
Although ABCA1 is expressed inmany cells in the body, recent
studies in hepatocyte- and intestinal epithelium-specificAbca1
knock-out mice suggest that the liver contributes 70–80% of
the plasma HDL pool, whereas the intestine contributes
20–30% (16, 17). Although mobilization of excess FC from
macrophages is dependent onABCA1 and results in the forma-
tion of nascent HDL particles, transplantation of bone marrow
from Abca1 knock-out (KO) mice into wild-type (WT) mice or
transplantation of WT marrow into Abca1 KO recipients has
little effect on plasma HDL concentrations, suggesting that
macrophage ABCA1 expression hasminimal impact on plasma
HDL concentrations (18, 19).
Macrophages are a primary cell type involved in innate
immunity. Although macrophage ABCA1 has a minimal
impact on plasma lipid levels, there is evidence that its activity
modulates the inflammatory response of macrophages to
pathogen-associated molecules such as lipopolysaccharide
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(LPS) (20). Francone et al. (20) reported that LPS-induced sep-
tic shock was exacerbated in Abca1//Ldlr/ mice com-
pared with Ldlr/ mice, suggesting a potential relationship
between ABCA1 function and inflammation. However, macro-
phages from the Abca1//Ldlr/ mice were enriched
80-fold inCE content, and plasmaHDL concentrations in these
mice were extremely low. Thus, it is not clear whether the exac-
erbated pro-inflammatory response to LPS of macrophages
from Abca1//Ldlr/ mice was due to the massive cellular
CE accumulation, the absence of plasma HDL, or some other
alteration of macrophages.
In macrophages, excess FC accumulation induces cytotoxic-
ity and apoptosis, which is thought to be triggered through the
endoplasmic reticulum (ER) stress pathway (21–23). In addi-
tion, mounting evidence suggests an association between the
presence of lipid rafts in the plasma membrane and the pro-
inflammatory activation ofmacrophages by LPS (24–26). Lipid
rafts consist of an orderedmembranemicrodomain enriched in
FC, glycosphingolipid, and glycosylphosphatidylinositol-an-
chored proteins and are platforms for signal transduction (27,
28). Recently, Landry et al. (29) reported that ABCA1 overex-
pression in baby hamster kidney cells disrupted membrane
lipid rafts, enhanced FC efflux to apoA-I, and resulted in a sig-
nificant redistribution of FC and sphingomyelin from lipid rafts
to non-raft regions of the membrane. Conversely, Koseki et al.
(30) reported an increase in lipid raft content and an acceler-
ated tumor necrosis factor- (TNF-) secretion induced by
LPS in Abca1 KO macrophages and suggested an association
between macrophage membrane lipid raft content and cellular
sensitivity to LPS.
To determine the role of macrophage ABCA1 in innate
immunity with minimal alteration in lipid and lipoprotein
metabolism, we developed the macrophage-specific Abca1 KO
(Abca1M/M) mouse by crossing the conditionally targeted
(“floxed”)Abca1mouse with mice expressing Cre recombinase
“knocked in” to the lysozyme M locus. These mice were then
used to determine the effect of macrophage Abca1 gene dele-
tion on the concentration of plasma lipids and lipoproteins,
macrophage sterol accumulation, and the response of macro-
phages to a pro-inflammatory stimulus, LPS. Our results indi-
cate that a small increase inmembrane FC and lipid raft content
causes macrophage hypersensitivity to LPS in the absence of
significant changes in plasma lipid and lipoprotein concentra-
tions. Thus,macrophageABCA1 expression plays a critical reg-
ulatory role in plasmamembrane cholesterol/lipid raft homeo-
stasis and macrophage innate immune response.
EXPERIMENTAL PROCEDURES
Animals—Abca1 floxed mice were generated by insertion of
LoxP sites into introns 44 and 46 of the murine Abca1 gene
using homologous recombination as described previously (17).
Mice with macrophage-specific deletion of Abca1 were gener-
ated by crossing Abca1 floxed (Abca1flox/flox) mice with
C57BL/6 mice expressing the Cre recombinase transgene
under control of the lysozyme M promoter (B6.129-
Lyzstm1(cre)Ifo/J, The Jackson Laboratory). Progeny from the
cross that were heterozygous at the Abca1 locus and inherited
the LysCre allele were identified by PCR (i.e. Abca1/M).
Intercrossing Abca1/M mice resulted in the production of
the Abca1/ (WT), Abca1/M (heterozygous), and
Abca1M/M (homozygous) mice used in this study. Abca1
total KO (Abca1/) mice were generated as reported previ-
ously (15). Animals were housed in a specific pathogen-free
facility with 12-h light/dark cycles and received a standard lab-
oratory chow diet. All animal procedures were approved by the
Wake Forest University School of Medicine Animal Care and
Use Committee.
Peritoneal Macrophage (PM) and Bone Marrow-derived
Macrophage (BMDM) Isolation and Culture—Elicited PMs
were collected 4 days after injection of 1ml of 10% thioglycolate
into the peritoneal cavity of 9–15-week-old mice as described
previously (17). PMs were suspended in RPMI 1640medium or
Dulbecco’s modified Eagle’s medium containing 10% heat-in-
activated fetal bovine serum (FBS) or 1%Nutridoma-SP (Roche
Applied Science), 100 units/ml penicillin, 100 g/ml strepto-
mycin, and 2 mM L-glutamine and then plated in tissue culture
plates and cultured at 37 °C under a 5% CO2 atmosphere. Two
hours later, non-adherent cells were removed by washing with
phosphate-buffered saline (PBS), and adherent macrophages
were used for studies. BMDMswere obtained as described pre-
viously with minor modification (31). Briefly, cleaned femurs
and tibias from mice were cut at one end, and the marrow was
collected by centrifugation into Eppendorf tubes and then
plated in Petri dishes (Fisher) in low glucose Dulbecco’s modi-
fied Eagle’s medium containing 30% L929 cell-conditioned
medium, 20% FBS, 2 mM L-glutamine, 1 mM sodium pyruvate,
100 units/ml penicillin, and 100 g/ml streptomycin for 7
days until the cells reached confluence. BMDMs were then
washed once with PBS and removed from the dishes with 0.53
mM EDTA (pH 7.4) and incubated overnight in tissue culture
plates with RPMI 1640 medium containing 1% Nutridoma-SP
before experiments were initiated.
Southern Blot Analysis—Southern blotting was performed as
described previously (17).
Western Blot Analysis of Macrophages—Protein expression
was determined by Western blot analysis of total cell protein
harvested frommacrophages using radioimmune precipitation
assay lysis buffer (50 mM Tris, 150 mM NaCl, 1% Nonidet P-40,
10% sodium cholate, and 1 mM EDTA) containing protease
inhibitors (1 mM phenylmethylsulfonyl fluoride, 1 g/ml pep-
statin, 1 g/ml leupeptin, and 1 g/ml aprotinin). Cell proteins
(50 g) were separated on 4–16% SDS-polyacrylamide gels,
transferred to nitrocellulose membranes (Schleicher & Schüll),
and incubated overnight at 4 °C with the following antibodies
depending on the experiment: rabbit anti-human/mouse
ABCA1 (17), rabbit anti-mouse CD14 (Abcam), rabbit anti-
mouse TLR4 (Cell Signaling Technology, Inc.), and rabbit anti-
mouse MyD88 and mouse anti-human/rat/mouse -actin
(Sigma). The blots were then incubated with horseradish per-
oxidase-linked anti-rabbit IgG or anti-mouse IgG (Amersham
Biosciences) at room temperature for 1 h. Immunoblots were
visualized with a chemiluminescent reagent (Pierce), and the
chemiluminescence was captured with an LSA-3000 imaging
system (Fujifilm Life Science) or Kodak X-Omat XLS-1 film.
Lipid Efflux Assay—FC and PL efflux assays from elicited
PMs were performed as described previously (17).
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Plasma Analyses—Plasma was isolated from blood collected
through the tail veins of mice fasted for 4 h. Plasma lipid con-
centrations were determined by enzymatic assays (32). Plasma
HDL cholesterol concentrations were measured as described
previously (17, 32). ApoA-I levels weremeasured by a sandwich
enzyme-linked immunosorbent assay (ELISA) (17, 33). Fast
protein liquid chromatography was performed using two
Superose 6 columns (1  30 cm; Amersham Biosciences) in
series, followed by total cholesterol enzymatic assay of each
eluted fraction.
Cholesterol Content in Macrophages—Cellular lipids were
extractedwith isopropyl alcohol (including 5-cholestane as an
internal standard) at room temperature overnight and analyzed
for cholesterol content by gas-liquid chromatography as
described previously (34).
Inflammatory Mediator Expression in LPS-treated Macro-
phages—After overnight incubation, PMs were switched to
serum-free RPMI 1640medium for 2 h before LPS stimulation.
BMDMs were incubated overnight in 1% Nutridoma-SP
medium before LPS stimulation. Macrophages were treated
with 100 ng/ml LPS from Salmonella typhimurium (Sigma) in
serum-free RPMI 1640 medium for 0–6 h, after which the cul-
ture supernatants were collected and stored at80 °C for cyto-
kine ELISA (BD Biosciences). Total RNA was isolated from
macrophages usingTRIzol reagent as described previously (17).
Relative mRNA expression of each target gene was analyzed in
triplicate, normalized to glyceraldehyde-3-phosphate dehydro-
genase, and expressed relative to WT macrophages without
LPS treatment using the 2CT method (35). Primers were
designed using the default settings of the manufacturer for the
Primer Express 2.0 program (Applied Biosystems) or frompub-
lished sequences and are listed in supplemental Table S1.
Plasma Concentration of Cytokines after LPS Injection into
Mice—Abca1/ or Abca1M/Mmice (8–12 weeks old) were
injected in the peritoneal cavity with LPS (3mg/kg) or pyrogen-
free PBS (vehicle). Three hours after injection, mice were killed
and bled by cardiac puncture, and plasma was isolated by cen-
trifugation at 12,000  g for 10 min and stored at 80 °C until
analyses were performed. The plasma levels of interleukin
(IL)-6 and IL-12p40 were measured by ELISA kits (BD Bio-
sciences) according to the manufacturer’s instructions. The
lower limit of detection for the cytokine assays was 15.6 pg/ml.
Analysis of Signal Pathways in the LPS-treated Macrophage—
Analysis of macrophage signaling pathways before and after
stimulation with LPS was performed using Western blot anal-
ysis and specific inhibitors. Macrophages were serum-starved
for 2 h prior to LPS stimulation and then treated with or with-
out 100 ng/ml LPS for 0–6 h, after which cells were processed
for Western blot analysis. Antibodies to access activation of
signaling pathways were purchased from Cell Signaling Tech-
nology, Inc. Immunoblots were visualized as described above.
In separate experiments, 2-h serum-starvedmacrophages were
pretreated for 1 h with IB inhibitor Bay 11-7082 (5.0 M; Cal-
biochem), MEK/ERK inhibitor U0126 (25 M; Calbiochem), or
p38 inhibitor (p38 MAPK inhibitor III; 2 M; Calbiochem) and
subsequently treatedwith 100ng/ml LPS for an additional 3 or 6 h
before RNA isolation for reverse transcription (RT)-PCR quanti-
fication of pro-inflammatory cytokine expression.
Small Interfering RNA (siRNA) Transfection—Elicited PMs
were isolated and cultured as described above. The medium
was replaced with antibiotic-free complete medium, and the
incubation was continued overnight, after which the control or
gene-specific siRNA (Abca1, CD14, or MyD88; 50 nM) was
transfected into macrophages with DharmaFECT reagent
(Dharmacon) according to the manufacturer’s protocol. To
evaluate silencing efficiency, RT-PCR of cellular RNA and
Western blot analysis of cell lysates harvested 48–72 h after
transfection were performed. siRNA-treated macrophages
were then incubated for 6 or 8 h with or without 100 ng/ml LPS
before analysis of cytokine expression by RT-PCR or ELISA as
described above, apoA-I-induced FC efflux, and sterol content
by gas-liquid chromatography.
Flow Cytometry—Exudates were harvested from peritoneal
cavities of mice 4 days after intraperitoneal injection of 10%
thioglycolate. After blocking the Fc receptor with purified
anti-mouse CD16/CD32 antibody (Fc receptor III/II; BD Bio-
sciences), peritoneal cells were incubated at 4 °C for 30 min
with rat IgG2a isotype control (phycoerythrin or fluorescein
isothiocyanate; eBioscience), anti-mouse F4/80 antibody (phy-
coerythrin; eBioscience), anti-mouse CD14 antibody (fluores-
cein isothiocyanate; eBioscience), or both anti-mouse CD14
and anti-mouse F4/80 antibodies. To visualize lipid rafts, peri-
toneal cells were first labeled with anti-mouse F4/80 anti-
body as described above and then rapidly stained with 10 ng
of Alexa Fluor 488-labeled cholera toxin B (CT-B) from
Vybrant lipid raft labeling kits (Invitrogen) for 10 min at
4 °C. Cell fluorescence was determined using a FACSCalibur
flow cytometer (BD Biosciences) and analyzed with FlowJo
software (Version 7.2.2).
Confocal Microscopy of Lipid Rafts in PMs—Lipid rafts in
PMs were stained using the Vybrant lipid raft labeling kit.
Briefly, elicited PMs were seeded onto circular coverslips
(Fisher) at a cell density of 0.6  105 macrophages/coverslip in
RPMI 1640 complete medium (plus 10% FBS and antibiotics).
Two hours later, non-adherent cells were removed by washing,
and macrophages were incubated for 24 h in RPMI 1640 com-
plete medium. After cells were washed once with chilled RPMI
1640 complete medium, 150 l of chilled Alexa Fluor 488-la-
beled CT-B conjugate (1 g/ml) was added to each coverslip.
Cells were incubated for 15 min at 4 °C. After washing with
chilled PBS, 150 l of chilled anti-CT-B antibody was added to
each coverslip to cross-link the CT-B lipid rafts, and cells were
then incubated for 15 min at 4 °C. After washing with chilled
PBS, cells were fixed in 4% paraformaldehyde for 20min at 4 °C.
Fixed cells were mounted with a Prolong antifade kit (Molecu-
lar Probes) before examination under a 20 objective using a
Model 510 laser scanning confocalmicroscope (Carl Zeiss AG).
Cholesterol Depletion and Repletion of Macrophages—
Cholesterol depletion and repletion of macrophages with
methyl--cyclodextrin (MCD) were performed as
described previously (36). Briefly, BMDMs were incubated
with or without prewarmed 10 mM MCD at 37 °C for 30
min to deplete cholesterol. Macrophages were then washed
with PBS and incubated in the absence or presence of cho-
lesterol (80 g/ml) and 1.5 mM MCD at 37 °C for 1 h to
reload macrophages with cholesterol. Then, macrophages
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were extracted with isopropyl alcohol tomeasure cholesterol
content by gas-liquid chromatography as described above or
incubated with or without 100 ng/ml LPS for 8 h before
quantification of cytokine gene expression by ELISA.
Expression of Sterol-responsive Genes—After overnight cul-
ture in RPMI 1640 medium containing 10% FBS, elicited PMs
were serum-starved in serum-free RPMI 1640 medium for 2 h
and then incubated with 10 M T0901317 or vehicle (Me2SO)
for 20 h. Cellular RNA was harvested, and RT-PCR was per-
formed to measure expression of liver X receptor (LXR) and
several LXR-responsive genes such as ABCG1 (ATP-binding
cassette transporterG1), phospholipid transfer protein, and apoE.
In separate experiments, elicited PMs were cultured over-
night in RPMI 1640 medium containing 10% FBS and then
incubated in serum-free RPMI 1640 medium for 8 h before
RNAwas harvested for RT-PCR quantification of SREBP2 (ste-
rol regulatory element-binding protein-2), 3-hydroxy-3-meth-
ylglutaryl-CoA reductase, 3-hydroxy-3-methylglutaryl-CoA
synthase, and low density lipoprotein receptor mRNAs. Primer
sequences are listed in supplemental Table 1.
Analysis of the ER Stress Pathway—After isolated and over-
night culture as described above, elicited PMs were serum-
starved for 2 h and then treated with or without 10 g/ml tuni-
camycin for 0–10 h. Expression of the ER stress proteins in the
treated cells was determined by Western blot analysis as
described above using antibodies to CHOP (C/EBP homolo-
gous protein; Santa Cruz Biotechnology) and BiP and IRE1
(Cell Signaling Technology, Inc.).
Statistics—Differences were compared with two-tailed Stu-
dent’s t test or one-way analysis of variance usingGraphPadPrism
software.p 0.05was considered statistically significant.Data are
presented as the means  S.D. unless indicated otherwise.
RESULTS
Creation of Macrophage-specific Abca1 KOMice—Mice that
specifically lack Abca1 in macrophages and neutrophils were
generated by crossing Abca1 floxed mice with mice expressing
Cre recombinase under the control of themacrophage/neutro-
phil-specific lysozyme M promoter (37). Conditional targeting
of the mouse Abca1 gene was achieved by flanking exons
45–46, which encode the second nucleotide-binding cassette,
with LoxP sites (designated by the arrowheads in the floxed
allele in Fig. 1A). Cre recombinase-mediated recombination
resulted in a KO allele missing exons 45 and 46 only in macro-
phages. Fig. 1B shows results from Southern blot analysis of
EcoRV-digested genomic DNA from kidney (control tissue)
and elicited PMs isolated from Abca1/ and Abca1M/M
littermates. Cre recombinase-mediated deletion of Abca1 was
evident in themacrophages fromAbca1M/Mmice, but not in
kidney tissue from these mice (Fig. 1B). A near-complete dele-
tion of ABCA1 protein expression in both freshly isolated elic-
ited PMs and BMDMs from Abca1M/M mice was also con-
firmed by Western blot analysis (Fig. 1C). Because ABCA1 is
highly responsive to transcriptional activation by LXR/retinoid
X receptor transcription factors (38, 39), we treated PMs with
an LXR agonist (T0901317) to maximize ABCA1 protein
FIGURE 1. Generation of macrophage-specific Abca1 knock-out (Abca1M/M) mice. A, targeting strategy of Abca1M/M mice. The schematic of the
3-region (exons 44 – 49) of the Abca1 gene shows WT (upper), floxed (middle), and KO (lower) Abca1 alleles. Cre recombinase-mediated deletion of exons 45
and 46 eliminates the second ATP-binding cassette, resulting in a KO allele. E, EcoRI; Rv, EcoRV; Bg2, BglII; H, HindIII; S, SacI. B, Southern blot of genomic kidney
(K) and peritoneal macrophage (M) DNAs from mice with WT (/) or floxed (M/M) alleles in the presence of lysozyme M Cre recombinase. DNA was
digested with EcoRV and hybridized with a probe to the genomic region between exons 44 and 45 in the Abca1 gene to produce the 6-kb WT, 7.3-kb floxed,
or 4.2-kb KO band. C, Western blot of cell lysates from cultured elicited PMs or BMDMs from WT (/) and Abca1M/M (M/M) mice with antibodies against
mouse ABCA1 and -actin (loading control). D, Western blot of cell lysates from cultured thioglycolate-elicited PMs after 18 h of incubation with or without 10
M T0901317 (LXR agonist).
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expression. Fig. 1D shows that 10 M T0901317 treatment
markedly increased ABCA1 expression in WT macrophages,
but induced only a very low level of ABCA1 expression in
Abca1M/M macrophages, supporting the conclusion that
ABCA1 expression in Abca1M/M macrophages was nearly
completely eliminated. In addition, resident macrophages in
Abca1M/Mmouse liver also lacked ABCA1 expression com-
pared with WT liver, as shown by immunofluorescent staining
of frozen liver sections (supplemental Fig. S1).
Macrophage-specific Deletion of Abca1 Eliminates Lipid Efflux
to Lipid-freeApoA-I—ABCA1mediates the essential initial step in
HDLparticle formation by promoting the efflux of cellular FC and
PL to apoA-I (40, 41). To determine whether this essential func-
tion is eliminated in macrophages from Abca1M/M mice, we
studied lipid efflux in the presence or absence of T0901317 using
elicited PMs fromWT, Abca1M/M, and Abca1 total KO mice.
Asexpected, in theabsenceof apoA-I, FC(Fig. 2A) andPL(Fig. 2B)
efflux from macrophages was low and similar for all three geno-
types. However, in the presence of apoA-I or apoA-I and
T0901317, macrophages from WT mice exhibited a substantial
increase in FC and PL efflux, whereas macrophages from
Abca1M/M or total KO mice demonstrated only background
efflux, demonstrating that lipid efflux was completely eliminated
inAbca1M/Mmacrophages.
Increased FC Accumulation in Cultured Abca1M/M
Macrophages—ABCA1 is an important determinant of macro-
phage sterol homeostasis. The severe impairment of choles-
terol efflux to lipid-free apoA-I in
Abca1-deficient macrophages (Fig.
2A) would be expected to result in
cholesterol accumulation. To deter-
mine whether this was the case, we
measured FC and CE content in 1)
elicited PMs after overnight cul-
ture in medium supplemented
with or without 10% FBS, 2)
BMDMs after overnight incuba-
tion in RPMI 1640 medium with
1% Nutridoma-SP, and 3) freshly
isolated elicited PMs (i.e. 2 h post-
harvest). Fig. 2 (C and D) shows
that Abca1M/M macrophages
had a slightly but statistically sig-
nificant higher amount of FC
(13%) compared with WT mac-
rophages after overnight culture
(PMs, 48.4  1.0 versus 42.7  0.4
g of FC/mg of cell protein, and
BMDMs, 36.3  0.6 versus 32.1 
0.2 g of FC/mg of cell protein,
respectively). CE content was
either undetectable or very low in
overnight cultured PMs or
BMDMs regardless of genotype
(Fig. 2, C and D). Freshly isolated
Abca1M/M PMs also had signif-
icantly higher FC content (7.4%)
compared with WT PMs (33.2 
0.5 versus 30.9  1.2 g of FC/mg of cell protein) (Fig. 2E),
and there was a gene dosage-dependent increase in FC con-
tent with successive deletion of Abca1 alleles (i.e.
Abca1M/M 	 Abca1/M 	 Abca1/). However, unlike
macrophages cultured overnight, freshly isolated
Abca1M/M PMs had a 2.4-fold higher CE content com-
pared with WT macrophages and exhibited a gene dosage-
related increase in CE content (7.7  0.5, 10.0  2.0, and
18.8  4.3 g of CE/mg of cell protein for WT, Abca1/M,
and Abca1M/M, respectively) (Fig. 2E). Thus, overnight
incubation of macrophages resulted in a shift of cellular
cholesterol from CE to FC stores, presumably due to CE
hydrolysis.
Plasma Lipid, Lipoprotein, and ApoA-I Concentrations in
Chow-fedAbca1M/MMice—Fasting total plasma lipid, lipopro-
tein, and apoA-I concentrations in Abca1/, Abca1/M, and
Abca1M/Mmice were not different among the three genotypes
(Table 1). Fast protein liquid chromatography fractionation of
whole plasma also showed a similar plasma lipoprotein profile
among these three genotypes of mice (supplemental Fig. S2).
These data support the conclusion of previous bone marrow
transplant studies (18, 19) that macrophage ABCA1 expression
contributes minimally to the plasma HDL pool.
ABCA1-deficient Macrophages Are Hypersensitive to LPS—
Macrophages fromAbca1 total KOmice are pro-inflammatory
and hypersensitive to LPS stimulation (20, 30). To determine
the activation state of macrophages from Abca1M/M mice
FIGURE 2. Decreased lipid efflux and increased cholesterol accumulation in cultured macrophages from
Abca1M/M mice. A and B, thioglycolate-elicited PMs were isolated from WT (/), Abca1M/M (M/M),
and Abca1 total KO (/) mice; radiolabeled with [3H]cholesterol or [14C]choline chloride for 24 h; and then
incubated with 10 M T0901317 or vehicle (Me2SO) for an additional 24 h. Lipid efflux was initiated by incu-
bating macrophages with or without 20 g/ml apoA-I  T0901317. Radiolabel in the medium and the cellular
isopropyl alcohol extracts were quantified, and percentage efflux was calculated as the ratio of radioactivity in
the medium divided by the total radioactivity (cells  medium)  100%. C–E, after the specified incubation
conditions, cells were extracted with isopropyl alcohol containing 5-cholestane as an internal standard, and
free and total cholesterol were quantified by gas-liquid chromatography. CE was calculated as (total  free
cholesterol)  1.67. Cell protein was determined using the Lowry protein assay. C, after 2 h of incubation and
removal of non-adherent cells, PMs were cultured in RPMI 1640 medium overnight before cholesterol mass
measurement (n 
 four to five dishes of cells/genotype). D, after 7 days of culture in bone marrow medium,
BMDMs were incubated in 1% Nutridoma-SP medium overnight before measurement of cholesterol (n 
 four
to five dishes of cells/genotype). Data are the means  S.D. (assayed in triplicate). ND, not detectable. E, elicited
peritoneal cells were isolated from individual mice (n 
 3 for WT and Abca1M/M and 2 for Abca1/M),
incubated in 1% Nutridoma-SP medium for 2 h, and washed to remove non-adherent cells before cholesterol
measurement (n  four dishes of cells/mouse). *, p  0.05 compared with /.
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compared with those from WT mice, we performed in vitro
studies using LPS to activate culturedmacrophages. The results
in Fig. 3 (A and B) show a significant (p  0.05) increase in
mRNA expression of MCP-1 and cytokines such as IL-1,
TNF-, IL-6, IL-12, inducible nitric-oxide synthase, and COX2
(cyclooxygenase-2) in both PMs and BMDMs from
Abca1M/M mice in response to 6 h of LPS treatment com-
pared with WT mice. Similar results were obtained at earlier
and later time points (1, 3, and 18 h) (data not shown). Consist-
ent with the elevated mRNA levels, ELISA results demon-
strated significantly higher concentrations of pro-inflamma-
tory cytokines (IL-12p40, TNF-, and IL-6) in culture
supernatants from LPS-activated macrophages from
Abca1M/M mice compared with WT mice (Fig. 3, C and D).
The increased secretion of pro-inflammatory cytokines (IL-
12p40, TNF-, and IL-6) from Abca1M/M macrophages
peaked at 6 h of LPS stimulation compared with 1- and 3-h
treatments (data not shown). No significant differences in pro-
inflammatory cytokine expression prior to LPS stimulation
were observed between the two genotypes of macrophages
(data not shown). Taken together with the data in Fig. 2 (C and
D), the results demonstrate that loss of ABCA1 inmacrophages
results in hypersensitivity to LPS with a minor but significant
elevation in macrophage FC content and very low or undetect-
able CE content.
Elevated Plasma Levels of Pro-inflammatory Cytokines in
LPS-treated Abca1M/M Mice—To evaluate the effect of an
acute pro-inflammatory stimulus in vivo, mice were injected in
the peritoneal cavity with 3 mg of LPS/kg of body weight, and
plasma levels of several pro-inflammatory cytokines were
measured 3 h post-injection. Plasma IL-6 and IL-12p40 con-
centrations were significantly higher in LPS-stimulated
Abca1M/M mice compared with WT mice (IL-6, 156.8 
13.9 versus 101.1 16.2 ng/ml, p 0.05; and IL-12p40, 113.3
9.6 versus 79.6  8.2 ng/ml, p  0.05) (Fig. 3E), supporting the
in vitro data that macrophages lacking ABCA1 are hypersensi-
tive to LPS.
NF-B and MAPK Signaling Pathways Are Involved in
Hypersensitivity of Abca1M/M Macrophages to LPS
Stimulation—The NF-B (42), MAPK (43), and phosphatidyl-
inositol 3-kinase/Akt (44) pathways are three major signaling
pathways involved in TLR4 (Toll-like receptor 4)-mediated
pro-inflammatory cytokine expression in macrophages. To
determine the activation state of these pathways in
Abca1M/M versus WT macrophages, BMDMs from each
genotype of mice were stimulated with 100 ng/ml LPS for 1, 3,
or 6 h before isolating cell lysates for Western blot analysis of
key intermediates in these signaling pathways. As shown in Fig.
4A, the extent of degradation of IB (inhibitory B protein )
was much greater at 1 h in Abca1M/M macrophages com-
pared with WT macrophages, indicative of increased NF-B
pathway activation, and there was also a considerable increase
in phospho-ERK1/2, phospho-JNK (c-Jun N-terminal kinase),
and phospho-P38 during the time course of LPS stimulation,
suggesting that both the NF-B and MAPK pathways are
involved in the pro-inflammatory activation of macrophages in
the absence of ABCA1. In contrast, the active phosphatase or
kinases in the phosphatidylinositol 3-kinase/Akt pathway
(phospho-PTEN, phospho-PDK1, phospho-Raf, phospho-
GSK3, and phospho-Akt) did not show any apparent differ-
ences between the two genotypes. Additionally, pretreating
FIGURE 3. Abca1M/M macrophages are hypersensitive to LPS. After over-
night culture in 10% FBS containing RPMI 1640 medium, PMs and BMDMs were
incubated for 2 h in serum-free medium and then treated with 100 ng/ml LPS for
6 h. Cytokine and chemokine mRNA expression and protein secretion were ana-
lyzed by real-time PCR and ELISA, respectively. LPS stimulated higher mRNA (A
and B) and protein (C and D) expression of cytokines and chemokines in
Abca1M/M (M/M) PMs (A and C) and BMDMs (B and D) relative to WT (/)
macrophages. Data are the means  S.D. (assayed in triplicate). Experiments
were repeated at least twice. iNOS, inducible nitric-oxide synthase. E, plasma lev-
els of inflammatory cytokines in LPS-injected mice. Mice were given an intraperi-
toneal injection of pyrogen-free PBS or 3 mg of LPS/kg of body weight and killed
3 h after injection. Plasma cytokine levels were determined using commercially
available ELISA kits as described under “Experimental Procedures.” Data are the
means  S.D. for LPS-injected mice (n 
 four to five mice/genotype). Values for
PBS-injected mice were below the detection limits of the assay (16.5 pg/ml). *, p
0.05 compared with /.
TABLE 1
Plasma lipid and apolipoprotein concentrations for chow-fed WT and macrophage-specific Abca1 KO mice
Values are the means  S.D. Blood was obtained from chow-fed mice after a 4-h fast. The number of mice is indicated in parentheses. /, WT; /M, heterozygous
macrophage-specific Abca1 KO; M/M, homozygous macrophage-specific Abca1 KO; /, Abca1 total KO; TPC, total plasma cholesterol; HDL-C, HDL cholesterol;
TG, triglyceride; ND, not detectable.
Abca1 genotype TPC HDL-C FC PL TG ApoA-I
mg/dl mg/dl mg/dl mg/dl mg/dl mg/dl
/ 98  16 (18) 86  17 (13) 21  6 (12) 214  37 (12) 29  14 (12) 73  21 (7)
/M 98  20 (30) 83  12 (11) 19  4 (23) 212  60 (25) 22  9 (24) 77  25 (9)
M/M 97  24 (17) 82  18 (11) 20  8 (12) 221  64 (11) 32  19 (24) 68  19 (8)
/ 13  0.5 (3) 8  1 (3) ND ND ND ND
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both WT and Abca1M/M macrophages with inhibitors of
either the NF-B or MAPK pathway (IB phosphorylation
inhibitor Bay 11-7082, ERK1/2 inhibitor U0126, and p38 inhib-
itor p38 MAPK inhibitor III) before
cells were challenged with LPS dra-
matically attenuated LPS-induced
cytokine expression in macro-
phages from both genotypes and
dampened the LPS-induced hyper-
sensitivity of macrophages resulting
from loss of ABCA1 (Fig. 4, B and
C). The fact that no one inhibitor
completely eliminated the hyper-
sensitivity of Abca1M/M macro-
phages to LPS suggests thatmultiple
pathways of TLR4 signaling are
involved.
Hyperactivation of ABCA1-defi-
cient Macrophages Is Mediated
through a MyD88-dependent Path-
way—The binding of LPS to the
TLR4/CD14 receptor cluster ini-
tiates the recruitment of down-
stream adaptor proteins such as
MyD88 (myeloid differentiation
primary-response protein 88), fol-
lowed by activation of MyD88-de-
pendent and MyD88-independent
pathways that ultimately lead to the
release of inflammatory mediators
(45). Our data showed that
enhanced inflammatory activation
of Abca1M/M macrophages by
LPS was independent of cellular
CD14 expression (supplemental
Fig. S3). To determine whether the
hypersensitivity of Abca1M/M
macrophages to LPS is mediated
through a MyD88-dependent path-
way, we examined basal and LPS-
stimulated MyD88 and cytokine
expression before and after siRNA
transfection to silence MyD88.
MyD88 expression before and after
LPS stimulation was not different
between WT and Abca1M/M
macrophages, demonstrating the
ABCA1 deletion did not affect
MyD88 expression (Fig. 5A). Silenc-
ing of MyD88 resulted in 	85%
reduction of expression in both gen-
otypes of mice (Fig. 5B) and elimi-
nated the hypersensitivity of
Abca1M/M macrophages to LPS
stimulation (Fig. 5C), demonstrat-
ing that the hyper-responsiveness of
Abca1M/M macrophages to LPS
wasmediated through aMyD88-de-
pendent pathway.
Acute Silencing of Macrophage ABCA1 Results in Reduced
FC Efflux, Increased FC Content, and Increased Sensitivity to
FIGURE 4. NF-B and MAPK pathways are involved in the hypersensitivity of Abca1M/M macrophages
to LPS. A, BMDMs from WT (/) or Abca1M/M (M/M) mice were treated for 0, 1, 3, or 6 h with 100 ng/ml
LPS. Cell lysates were harvested, followed by immunoblotting with the indicated antibodies. B, elicited PMs
from mice were pretreated for 1 h with the IB inhibitor Bay 11-7082 (5.0 M) before challenge with 100 ng/ml
LPS for 6 h. Cellular RNA was then harvested to quantify inflammatory gene expression by quantitative RT-PCR.
iNOS, inducible nitric-oxide synthase. C, BMDMs were pretreated for 1 h with 25 M U0126 (MEK/ERK inhibitor)
or 2 M p38 MAPK inhibitor III (P38iIII) and then treated with 100 ng/ml LPS for 3 h before quantification of
inflammatory gene expression by RT-PCR. Data are presented as the means  S.D. (assayed in triplicate).
Experiments were repeated twice. *, p  0.05 compared with /.
FIGURE 5. Enhanced LPS-stimulated activation of Abca1M/M macrophages is MyD88-dependent. A, shown
are the results from Western blot analysis of CD14, TLR4, and MyD88 protein expression in BMDMs from WT (/)
and Abca1M/M (M/M) mice after in vitro treatment with 100 ng/ml LPS for 0, 30, 60, and 180 min. B, MyD88
expression was silenced by transfecting elicited PMs from WT or Abca1M/M mice with the indicated siRNAs for 72 h
before challenging the cells with 100 ng/ml LPS for 6 h. Western blotting was performed to determine protein
silencing efficiency. C, quantitative RT-PCR was performed to quantify cytokine mRNA expression after MyD88
silencing. Data are presented as the means  S.D. (assayed in triplicate). *, p  0.05 compared with /.
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LPS—To determine whether acute silencing of ABCA1 in
macrophages results in increased sterol content and LPS
hypersensitivity, we transfected WT macrophages with con-
trol or ABCA1 siRNA. ABCA1 mRNA expression was
decreased by 80% in cells transfected with ABCA1 siRNA
relative to the control (Fig. 6A). Acute silencing of ABCA1
expression in WT macrophages resulted in a 70% reduction
of apoA-I-mediated FC efflux (Fig. 6B), a statistically signif-
icant 5% increase in FC content (31.7  1.0 versus 33.3  0.9
g/mg of protein, p  0.05), and a 45% increase in CE con-
tent (15.7  2.6 versus 22.7  1.3 g/mg of protein, p  0.05)
(Fig. 6C). Furthermore, silencing of ABCA1 in macrophages
led to a significantly higher level of secretion of TNF- and
IL-12p40, but not IL-6, after LPS stimulation compared with
control siRNA-transfected macrophages (Fig. 6D). These
data demonstrate that acute silencing of ABCA1 in macro-
phages results in a pro-inflammatory phenotype that is sim-
ilar to that of macrophages fromAbca1M/Mmice and sup-
port an important role of macrophage ABCA1 expression in
regulating macrophage cholesterol homeostasis and innate
immune response.
Abca1M/M Macrophages Have an Increase in Membrane
Lipid Rafts—Specialized regions of the membrane known as
lipid rafts are enriched in cholesterol and sphingomyelin and
form platforms for extracellular signal transduction. To deter-
mine whether the increase in cellular FC in Abca1M/M
macrophages results in an increase inmembrane lipid raft con-
tent, we stained live PMs fromWTandAbca1M/Mmicewith
Alexa Fluor 488-labeled CT-B, which binds to the pentasaccha-
ride chain of ganglioside GM1, a raft-associated lipid. Fig. 7A
shows the confocal laser scanning images of PMs visualized
with CT-B. There was a trend toward brighter fluorescence and
more punctuate staining in macrophages with deletion of
ABCA1 relative toWTmacrophages, suggesting an increase in
lipid rafts (Fig. 7A). To investigate this trend quantitatively, we
stained thioglycolate-elicited total peritoneal cells with phyco-
erythrin-labeled anti-mouse F4/80 antibody and Alexa Fluor
488-labeled CT-B and then analyzed the cells by flow cytom-
etry. As shown in Fig. 7B, F4/80-gated cells (macrophage pop-
ulation) from Abca1M/M mice had a significantly higher
CT-B staining intensity compared with cells from WT mice,
supporting the conclusion of increased lipid rafts.
Cholesterol Depletion and Repletion in Macrophages Corre-
late with Macrophage Hypersensitivity to LPS—MCD has
been shown to disrupt lipid rafts by extracting membrane cho-
lesterol, whereas cholesterol-loaded MCD can replete the
plasma membrane with cholesterol (36, 46, 47). To determine
whether the pro-inflammatory state of the Abca1M/M mac-
rophages could be reduced by depleting FC, we pretreatedWT
and Abca1M/M BMDMs with 10 mM MCD for 30 min at
37 °C before stimulating cells with LPS (100 ng/ml) for 8 h. Fig.
7C shows that incubation with 10mMMCD significantly low-
ered cellular FC content in both WT macrophages (35.8  1.9
to 23.8 1.6g/mg of protein) andAbca1M/Mmacrophages
(40.0  1.2 to 23.4  0.4 g/mg of protein), resulting in similar
FC content between the two genotypes. Cholesterol depletion
with MCD significantly reduced LPS-induced BMDM secre-
tion of inflammatory cytokines (TNF-, IL-6, and IL-12p40) to
equivalent levels for WT and Abca1M/M BMDMs (Fig. 7,
D–F). Furthermore, incubation of cholesterol-depleted
BMDMs with cholesterol-loaded MCD partially restored the
FC difference betweenWTmacrophages (23.8  1.6 to 31.9 
0.5 g/mg of protein) and Abca1M/M macrophages (23.4 
0.4 to 33.4  1.2 g/mg of protein), resulting in a statistically
significant higher level of FC in Abca1M/M BMDMs com-
pared with WT BMDMs (Fig. 7C). Cholesterol repletion also
resulted in increased cytokine secretion for macrophages from
both genotypes compared with cholesterol-depleted BMDMs,
and the difference in cytokine secretion between WT and
Abca1M/M BMDMs was recovered for IL-12p40 (Fig. 7F),
even though the FC enrichment was only 5% higher in
Abca1M/M BMDMs compared with WT BMDMs after
repletion. These data establish a direct relationship between
macrophage FC content and hypersensitivity to LPS and sug-
gest that the hypersensitivity ofAbca1M/MBMDMs to LPS is
due to the increase in membrane FC and lipid rafts.
FC Accumulation in Abca1M/M Macrophages Fails to Acti-
vate LXR-responsive Genes and Cholesterol Biosynthetic Genes or
Exacerbates theUnfolded Protein Response (UPR)—The increased
lipid raft content of Abca1M/M macrophages suggested
that the increase in FC was localized primarily to the plasma
membrane. To obtain additional support for this concept, we
measured the expression of LXR-responsive genes, which
are activated by oxysterols when FC accumulation occurs in
cells. Expression of LXR-responsive genes was less in
Abca1M/M macrophages compared with WT macro-
phages, and the difference in response between the two gen-
otypes was maintained with synthetic LXR agonist stimula-
FIGURE 6. Acute silencing of Abca1 in WT macrophages results in increased
free cholesterol accumulation and pro-inflammatory response to LPS. PMs
from WT mice were transfected with 50 nM control or ABCA1 siRNA for 48 h.
A, quantitative RT-PCR was performed to quantify ABCA1 mRNA expression in
control and ABCA1 siRNA-transfected cells. B, transfected macrophages were
radiolabeled with [3H]cholesterol for 24 h and then equilibrated with bovine
serum albumin for an additional 2 h. FC efflux was initiated by incubating
macrophages with or without 20 g/ml apoA-I for 8 h. Radiolabel in the
medium and the cellular isopropyl alcohol extracts were quantified, and per-
centage efflux was calculated as the ratio of radioactivity in the medium
divided by the total radioactivity (cells  medium)  100%. C, cellular lipid
was extracted with isopropyl alcohol to measure FC and CE content by gas-
liquid chromatography (means  S.D., n 
 four to five dishes of cells/group).
D, macrophages were incubated with or without 100 ng/ml LPS for 8 h, and
pro-inflammatory gene expression was measured by ELISA (means  S.D.,
n 
 4). *, p  0.05 compared with control siRNA.
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tion (Fig. 8A). The decrease in LXR-responsive genes may be
related to the lower expression of LXR and LXR in
Abca1M/Mmacrophages (Fig. 8B). FC accumulation in the
ER results in down-regulation of the cholesterol biosynthetic
pathway through retention of SREBP2 in the ER (48). However,
we did not see a decrease in mRNA for SREBP2, its target cho-
lesterol biosynthetic genes such as 3-hydroxy-3-methylglu-
taryl-CoA reductase and 3-hydroxy-3-methylglutaryl-CoA
synthase, or its cholesterol uptake genes such as the low density
lipoprotein receptor (Fig. 8C). Finally, FC accumulation in the
ER can also cause ER stress, resulting in activation of the
UPR (49). To determine whether activation of the UPR is
enhanced in Abca1M/M macrophages, we analyzed the
expression of BiP, IRE1, and CHOP by Western blot anal-
ysis after tunicamycin treatment of WT and Abca1M/M
macrophages to induce ER stress. As expected, tunicamycin
treatment of macrophages resulted in induction of the UPR
with increased expression of BiP, CHOP, and IRE1 (Fig.
8D). However, there was no evidence that the UPR was
enhanced in Abca1M/M compared with the WT, as
expression of the three proteins
was similar between the two geno-
types. Taken together, these results
suggest that the FC enrichment in
Abca1M/M macrophages was not
being sensed by the ER, but more
likely was confined to the plasma
membrane.
DISCUSSION
Macrophages are key players in
the pathogenesis of atherosclerosis
(50). They are an integral cell type in
the innate immune response and are
involved in processing of excess
lipid from phagocytosis of apopto-
tic/necrotic cells or from uptake of
modified lipoproteins at sites of
inflammation. A recent study has
suggested that whole body deletion
ofABCA1 in Ldlr/mice results in
massive macrophage cholesterol
accumulation and a pro-inflamma-
tory phenotype (20). However, the
association between macrophage
cholesterol accumulation and the
pro-inflammatory state is poorly
understood. Using a unique animal
model with targeted deletion of
Abca1 in macrophages, we have
documented that macrophages
lacking ABCA1 are hypersensitive
to LPS stimulation in vivo and in
vitro via a MyD88-dependent sig-
naling pathway in the absence of
changes in plasma lipid and lipopro-
tein concentrations. The hypersen-
sitivity to LPS is dependent on sub-
tle increases in cell membrane cholesterol and lipid raft
content, suggesting an important role of ABCA1 in the regula-
tion of innate immunity through modulation of plasma mem-
brane cholesterol and lipid rafts. Thus, macrophage ABCA1
expression may protect against atherosclerosis by at least two
mechanisms, facilitating the net removal of excess lipid from
macrophages and dampening pro-inflammatory MyD88-
dependent signaling pathways by reduction of cellular lipid raft
content.
Since its discovery, ABCA1 has been shown to be absolutely
essential for plasma HDL formation and critical in preventing
the accumulation of excess lipid in macrophages (5, 6, 8).
Recent studies involving cell-specific Abca1 KOmouse models
have shown that liver and intestine are the twomost important
organs contributing to the plasmaHDL pool (16, 17). However,
ABCA1 is variably expressed in most cells of the body (1, 2),
including macrophages. Bone marrow transplantation studies
have shown that bone marrow ABCA1 expression does not
affect plasma HDL cholesterol concentrations (18, 19, 51). In
agreement with these studies, we have shown that the plasma
FIGURE 7. Macrophages from Abca1M/M mice have increased membrane lipid rafts. A, lipid raft staining
of elicited PMs was performed with fluorescently labeled CT-B as described under “Experimental Procedures.”
Images were captured under a 20 objective using a Zeiss Model 510 laser scanning confocal microscope.
Images are representative at least 50 fields of three coverslips/genotype. Scale bars 
 10 m. B, shown are the
results from flow cytometric analysis of macrophage lipid rafts. Cells were isolated from peritoneal cavity fluid
of mice 4 days after intraperitoneal injection of thioglycolate and were incubated with phycoerythrin-labeled
anti-mouse F4/80 antibody and Alexa Fluor 488-labeled CT-B. A representative intensity plot for F4/80-gated
cells from both genotypes of mice is shown in the left panel, and the average data (means  S.D.) from WT
(/; n 
 4) and Abca1M/M (M/M; n 
 3) mice are shown in the right panel. C–F, cholesterol depletion
and repletion using MCD abolished and partially restored the hypersensitivity of Abca1M/M macrophages
to LPS, respectively. BMDMs from WT and Abca1M/M mice were incubated with or without 10 mM MCD at
37 °C for 30 min to deplete cells of cholesterol. Some dishes of cells were then repleted with cholesterol by
incubation with cholesterol-loaded MCD (80 g/ml FC solubilized with 1.5 mM MCD; 1 h at 37 °C). Cells were
then harvested for cholesterol analysis by gas-liquid chromatography (C) or incubated with or without LPS (100
ng/ml; 8 h) before measuring cytokine concentration in the medium by ELISA (D–F). *, p  0.05 for the indicated
comparisons.
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lipid and lipoprotein phenotype is indistinguishable between
WT and Abca1M/M mice on a chow diet (Table 1 and sup-
plemental Fig. S2). Our data were generated from a novel
mouse model with the deletion of Abca1 restricted to macro-
phages and neutrophils, in which ABCA1 protein expression
was 5% of the WT, even after maximal up-regulation of gene
transcription with a synthetic LXR agonist (Fig. 1). Taken
together, these studies prove that macrophage ABCA1 has a
minimal role in determining plasma HDL concentrations.
Cholesterol accumulation in macrophages is associated with
a pro-inflammatory phenotype (22). Macrophages have multi-
ple ways to protect against accumulation of toxic levels of FC,
including increased esterification of FC to form relatively inert
CE, increased PL synthesis to solubilize excess FC, and
increased efflux of FC (52). An increase in FC and oxygenated
derivatives (i.e. oxysterols) results in activation of LXR, which
increases transcription of multiple genes involved in choles-
terol efflux, includingAbca1,Abcg1, phospholipid transfer pro-
tein, and apoE (53). These multiple systems protect against
the accumulation of FC in the ER, which can activate the
UPR and ultimately lead to apoptosis (49). A previous study
with Abca1/ mice in the atherosclerosis-prone Ldlr/
background documented the existence of pro-inflammatory
macrophages compared with Ldlr/ mice, suggesting a role
for ABCA1 expression in the innate immune response to the
TLR4 agonist LPS (20). Although the molecular explanation
for the hyper-responsiveness to LPS in that study is not known,
it likely was related to an 80-fold
increase in CE, the lack of plasma
HDL, or both. Our study shows that
macrophages from Abca1M/M
mice are hyper-responsive to LPS in
vivo and in vitro compared with
macrophages from WT mice, with
modest accumulation of CE
(2.4-fold in freshly isolated PMs)
(Fig. 2E) and no change in plasma
lipoprotein concentration. Acute
silencing of ABCA1 in vitro also
results in significant increases in FC
and CE accumulation and hyper-
sensitivity to LPS (Fig. 6). The extent
to which the higher cellular CE con-
tent contributes to the hyper-respon-
siveness of Abca1M/M macro-
phages to LPS in vivo and in vitro is
unknown. However, hyper-respon-
siveness to LPS stimulation was
observed for freshly isolated PMs as
well as PM and BMDMs cultured
for extended periods of time, even
though CE content was non-detect-
able or very low after extended cul-
ture, suggesting that elevated FC,
not CE, was responsible for the
hypersensitivity (Fig. 2). The
increase in FC and the MyD88
dependence of the hypersensitivity
to LPS suggested an alteration at the proximal part of the TLR4
signaling pathway, which was verified by direct experimenta-
tion. 1) Freshly isolated PMs had a significant increase in lipid
raft content (Fig. 7, A and B). 2) Depletion of membrane lipid
raft cholesterol with MCD dampened the heightened inflam-
matory response of macrophages to LPS and eliminated the
difference in responsiveness to LPS between Abca1M/M and
WT macrophages (Fig. 7, C–F). 3) Cholesterol repletion
increased FC accumulation inmacrophages, enhanced the pro-
inflammatory response of macrophages to LPS (Fig. 7, C–F),
and also partially restored their hypersensitivity to LPS in
Abca1M/M macrophages (shown by significantly increased
IL-12p40 expression in Fig. 7F) relative to WT macrophages.
Overall, our data strongly support the concept that increased
macrophage cellular FC and lipid raft content, not CE accumu-
lation, is the primary explanation for Abca1M/M macro-
phage hypersensitivity to LPS.
Several recent studies have shown that ABCA1 expression
affects cellular lipid raft content and distribution. One study
demonstrated that overexpression of ABCA1 in baby hamster
kidney cells resulted in the redistribution of FC from lipid rafts
to non-raft regions of the cell membrane (29). Another study
showed that cultured macrophages from Abca1 total KO mice
had increased staining for lipid rafts, increased raft FC, and
increased secretion of TNF- in response to LPS (30). Our
results in Abca1M/M mice document increased lipid raft
staining in macrophages from freshly isolated elicited perito-
FIGURE 8. Free cholesterol accumulation in macrophages from Abca1M/M mice is not sensed by the ER.
A and B, shown is the lower expression of LXR target genes and LXRs in Abca1M/M (M/M) macrophages.
Elicited PMs were treated with Me2SO (DMSO; vehicle) or 10 M T0901317 (T comp.) for 20 h. Cellular RNA was
harvested, and RT-PCR was performed to measure expression of LXR-responsive genes (A) and expression of
LXR/ (B). Assays were performed in triplicate, and data were normalized to the level of gene expression in WT
(/) macrophages treated with vehicle. PLTP, phospholipid transfer protein. C, expression of sterol-sensing
genes was unaltered in Abca1M/M macrophages. Elicited PMs were isolated and cultured overnight and then
incubated in serum-free RPMI 1640 medium for 8 h. Gene expression was measured by RT-PCR after RNA
isolation. Assays were performed in triplicate, and the data were normalized to the gene expression level in WT
macrophages. HMGCoA, 3-hydroxy-3-methylglutaryl-CoA; LDLr, low density lipoprotein receptor. D, ER stress
was not enhanced in Abca1M/M macrophages. Elicited PMs (n 
 three dishes of cells/genotype) were treated
with 10 g/ml tunicamycin (TM) for 0 –10 h. The ER stress proteins were analyzed by Western blotting. *, p 
0.05 for the indicated comparisons.
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neal cells, suggesting that the increase in FC and lipid raft con-
tent occurs in vivo and is not an artifact of tissue culture. The
increase in FC sensitized the proximal steps of TLR4 signaling
asMyD88 silencing eliminated the hypersensitivity to LPS (Fig.
5, B and C). Our results also suggest that the FC enrichment in
Abca1M/M macrophages is largely restricted to the plasma
membrane based on the following observations: 1) the lack of
stimulation of LXR-responsive genes (Fig. 8A), 2) the lack of
stimulation of genes involved in cholesterol biosynthesis (Fig.
8C), and 3) the lack of stimulation of theUPR (Fig. 8D). Previous
studies have shown that an alteration in membrane FC content
affects cellular signaling (54, 55), suggesting that control of
membrane FC and lipid raft distribution is a critical component
of this regulation. Taken together, these data suggest that
ABCA1 may play a novel role in regulating signaling events
through control of lipid raft composition and distribution.
What is the physiological significance of ABCA1 regulation
of lipid rafts? Excessive accumulation of lipid by macrophages
through phagocytosis of apoptotic/necrotic cells or uptake of
oxidized lipoproteins results in activation of LXR by oxysterols.
The activation of LXR results in increased lipid efflux and
transrepression of pro-inflammatory gene expression (56, 57).
This concerted response protects against overstimulation of
the macrophage inflammatory activation upon lipid loading,
allowing an orderly processing of excess cellular lipid by
ABCA1- and ABCG1-mediated efflux to apoA-I and HDL,
respectively (58).Abca1 is a highly responsive gene to LXR acti-
vation (53), and our data suggest a secondmechanism bywhich
ABCA1may dampen the inflammatory response by decreasing
TLR4-induced transactivation of the NF-B andMAPK signal-
ing pathways. LPS activation of macrophages occurs when LPS
binds to CD14, which is a glycosylphosphatidylinositol-linked
receptor and is exclusively located in lipid rafts (26). However,
TLR4 andother adaptor proteinsmust be recruited to lipid rafts
upon LPS binding to CD14 to activate the canonical signaling
through NF-B and MAPK. Any process that disrupts or dis-
perses lipid rafts would lessen signaling potential by dispersing
receptors/co-receptors involved in transducing the extracellu-
lar signal across the plasmamembrane. Thus, cholesterol load-
ing ofmacrophages activates LXR, leading to transrepression of
pro-inflammatory genes and increased expression of ABCA1,
resulting in decreased cellular lipid raft content and diminished
transactivation of pro-inflammatory genes. A recent study has
also shown that the pro-inflammatory cytokine TNF- induces
ABCA1 expression through an NF-B-mediated pathway, sug-
gesting an additional pathway that could limit pro-inflamma-
tory pathway activation by further dispersion of lipid rafts and
diminished TLR4 signaling by increased ABCA1 expression
(59). Our conclusion of a novel role for ABCA1 in regulation of
membrane signaling is also supported by our recent demon-
stration of defective insulin release from pancreatic islet cells of
beta cell-specific Abca1 KOmice (60).
There is mounting evidence that human ABCA1 gene poly-
morphisms are associated with altered glucose metabolism,
onset of obesity, and insulin resistance in Mexican (61, 62),
French (63), and Japanese (64) populations, which were inde-
pendent of HDL formation in the latter study. In addition,
increasing evidence highlights that insulin resistance, a key
component of type 2 diabetes, is caused by chronic low-grade
inflammation (65, 66). For instance, macrophage-specific dis-
ruption of the pro-inflammatory NF-B activation pathway
eliminates insulin resistance in liver and skeletal muscle
induced by feeding mice a high fat/high sucrose diet (67).
Although polymorphisms in the human population likely affect
ABCA1 function in all tissues, our data suggest that loss of
ABCA1 function in macrophages may lead to increased low-
grade chronic inflammation in vivo, which may predispose one
to insulin resistance. Because saturated fatty acids can stimulate
inflammation in macrophages by activating TLR4 receptors
(68), we hypothesize that consumption of a high saturated fat
diet byAbca1M/Mmice compared withWTmice may result
in increased obesity and insulin resistance due to chronic low-
grade inflammation. Studies are ongoing to test this hypothesis.
If true, individuals with polymorphisms in ABCA1 that com-
promise function may be at increased risk for developing obe-
sity and insulin resistance when dietary consumption of satu-
rated fatty acids is high.
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